A phase 1, first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending intravenous dose study of VGL101, a novel TREM2 agonist, in healthy adult volunteers (HVS)
Year: 2023
Type: article
Authors: Andreas Meier, Spyros Papapetropoulos, Andrew Marsh, Kelly Neelon, Evan Thackaberry, David Stiles, Ryan O'Mara, Raj Rajagovindan
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4390260715